Glumetza Antitrust Case Sees More Settlements Ahead of Trial

Sept. 15, 2021, 3:17 PM

Assertio Therapeutics Inc. and Lupin Ltd. have settled many of the antitrust claims they face over the blockbuster diabetes drug Glumetza, less than a week after Bausch Health Cos. agreed to a $300 million deal, according to federal court filings in San Francisco.

The drug distributors leading part of the case disclosed an agreement in principle with Assertio in a notice filed Tuesday, the same day the magistrate judge overseeing a settlement conference indicated in a brief docket entry that it had culminated in a tentative deal with Lupin.

Several large retailer pharmacies bringing related lawsuits, meanwhile, voluntarily dropped their ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.